Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-12
2006-09-12
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S908000
Reexamination Certificate
active
07105560
ABSTRACT:
A method of treating multiple myeloma (MM) is provided comprising administering an amount of etodolac to a subject afflicted with MM that is effective to selectively reduce the viability of and/or to sensitize the cancer cells to an anti-cancer agent.
REFERENCES:
patent: 3053255 (1962-09-01), Meyer
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 3843480 (1974-10-01), Dreher
patent: 3843681 (1974-10-01), Demerson et al.
patent: 3939178 (1976-02-01), Demerson et al.
patent: 3948254 (1976-04-01), Zaffaroni
patent: 3948262 (1976-04-01), Zaffaroni
patent: 3974179 (1976-08-01), Demerson et al.
patent: 3993073 (1976-11-01), Zaffaroni
patent: 4041169 (1977-08-01), Demerson et al.
patent: 4179503 (1979-12-01), Asselin et al.
patent: 4310509 (1982-01-01), Berglund et al.
patent: 4337760 (1982-07-01), Rubin
patent: 4460562 (1984-07-01), Keith et al.
patent: 4466953 (1984-08-01), Keith et al.
patent: 4482534 (1984-11-01), Blank
patent: 4485097 (1984-11-01), Bell
patent: 4505891 (1985-03-01), Ito
patent: 4533540 (1985-08-01), Blank
patent: 4542012 (1985-09-01), Dell
patent: 4542013 (1985-09-01), Keith et al.
patent: 4560555 (1985-12-01), Snider
patent: 4585877 (1986-04-01), Demerson et al.
patent: 4597961 (1986-07-01), Etscorn
patent: 4608249 (1986-08-01), Otsuka
patent: 4686213 (1987-08-01), Ferdinandi et al.
patent: 4748252 (1988-05-01), Ferdinandi et al.
patent: 4806356 (1989-02-01), Shaw
patent: 4940587 (1990-07-01), Jenkins et al.
patent: 5561151 (1996-10-01), Young et al.
patent: 5599946 (1997-02-01), Vincenzo et al.
patent: 5776967 (1998-07-01), Kreft et al.
patent: 5780435 (1998-07-01), Garnick et al.
patent: 5811558 (1998-09-01), Adger et al.
patent: 5824699 (1998-10-01), Kreft et al.
patent: 5939455 (1999-08-01), Rephaeli
patent: 5955504 (1999-09-01), Wechter et al.
patent: 5968974 (1999-10-01), Kargman et al.
patent: 5981592 (1999-11-01), Wechter et al.
patent: 6110955 (2000-08-01), Nudelman et al.
patent: 6160018 (2000-12-01), Wechter et al.
patent: 6300313 (2001-10-01), Engel et al.
patent: 6552055 (2003-04-01), Spiegelman et al.
patent: 2002/0042375 (2002-04-01), Heimbrook et al.
patent: 2003/0004142 (2003-01-01), Prior et al.
patent: 2003/0004143 (2003-01-01), Prior et al.
patent: 1299577 (1992-04-01), None
patent: 0289262 (1986-11-01), None
patent: 1436893 (1976-05-01), None
patent: 96/28148 (1996-09-01), None
patent: WO-9748391 (1997-12-01), None
patent: 98/09603 (1998-03-01), None
patent: WO 98/09603 (1998-03-01), None
patent: 98/18490 (1998-05-01), None
patent: WO-98/40078 (1998-09-01), None
patent: 00/02555 (2000-01-01), None
patent: 00/13410 (2000-03-01), None
patent: WO-0106990 (2001-02-01), None
patent: WO-02/02125 (2002-01-01), None
patent: WO-0212188 (2002-02-01), None
Yasui et al., “SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma”, Blood, vol. 106, No. 2, (Jul. 15, 2005).
Abramson, S.B., et al., “The Mechanism of Action of Nonsteroidal Antiinflammatory Drugs”,Arthritis&Rheumatism,32 (1), pp. 1-9, (Jan. 1989).
Alexanian, R., et al., “The Treatment of Multiple Myeloma”,The New England Journal of Medicine,330 (7), pp. 484-489, (Feb. 17. 1994).
Barlogie, B., et al., “Prognostic Factors with High-Dose Melphalan for Refractory Multiple Myeloma”,Blood,72 (6), pp. 2015-2019, (Dec. 1988).
Bataille, R., et al., “Multiple Myeloma”,New England Journal of Medicine,336 (23), pp. 1657-1664, (Jun. 5, 1997).
Becker-Scharfenkamp, U., et al., “Evaluation of the Stereoselective Metabolism of the Chiral Analgesic Drug Etodolac by High-Performance Liquid Chromatography”,Journal of Chromatography,621 (2), pp. 199-207, (Nov. 24, 1993).
Bellosillo, B., et al., “Aspirin and Salicylate Induce Apoptosis and Activation of Caspases in B-Cell Chronic Lymphocytic Leukemia Cells”,Blood,92 (4), pp. 1406-1414, (Aug. 15, 1998).
Brocks, D.R., et al., “Etodolac Clinical Pharmacokinetics”,Clinical Pharmacokinetics,26 (4), pp. 259-274, (1994).
Carson, D.A., et al., “Oral Antilymphocyte Activity and Induction of Apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine”,Proc. Natl. Acad. Sci. USA,89 (7), pp. 2970-2974, (Apr. 1992).
Chinetti, G., et al., “Activation of Proliferator-activated Receptors α and γ Induces Apoptosis of Human Monocyte-derived Macrophages”,The Journal of Biological Chemistry,273 (40), pp. 25573-25580, (Oct. 2, 1998).
Cummingham, D., et al., “High-dose Melphalan for Multiple Myeloma: Long-term Follow-up Data”,Journal of Clinical Oncology,12 (4), pp. 764-768, (Apr. 1994).
Demerson, C.A., et al., “Etodolic Acid and Related Compounds. Chemistry and Antiinflammatory Actions of Some Potent Di- and Trisubstituted 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetic Acids”,Journal of Medicinal Chemistry,19 (3), pp. 391-395, (1976).
Demerson, C.A., et al., “Resolution of Etodolac and Antiinflammatory and Prostaglandin Synthetase Inhibiting Properties of the Enantiomers”,J. Med. Chem.,26 (12), pp. 1778-1780, (Dec. 1983).
Drachenberg, D.F., et al., “Treatment of Prostate Cancer: Watchful Waiting, Radical Prostatectomy, and Cryoablation”,Seminars in Surgical Oncology,18 (1), pp. 37-44, (Jan./Feb. 2000).
Duffy, C.P., et al., “Enhancement of Chemotherapeutic Drug Toxicity to Human Tumour Cells In Vitro by a Subset of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)”,European Journal of Cancer,34 (8), pp. 1250-1259, (Jul. 1998).
Hahnfeld, L.E., et al., “Prostate Cancer”,The Medical Clinics of North America—The Aging Male Patient,83 (5), pp. 1231-1245, (Sep. 1999).
Harousseau, J.L.; et al., “Double-Intensive Therapy in High-Risk Multiple Myeloma”,Blood,79 (11), pp. 2827-2833, (Jun. 1, 1992).
Krajewski, S., et al., “Detection of Multiple Antigens on Western Blots”,Analytical Biochemistry,236 (2), Article No. 0160, pp. 221-228, (May 1996).
Landis, S.H., et al., “Cancer Statistics, 1998”,CA Cancer J. Clin.,48 (1), pp. 6-29, (1998).
Lee, D.H., et al., “Proteasome Inhibitors: Valuable New Tools For Cell Biologists”,Trends in Cell Biology,8, pp. 397-403, (1998).
Lehmann, J.M., et al., “Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs”,The Journal of Biological Chemistry,272 (6), pp. 3406-3410, (Feb. 7, 1997).
Leoni, L.M., et al., “Induction of an Apoptotic Program in Cell-Free Extracts by 2-Chloro-2′-deoxyadenosine 5′-triphosphate and Cytochrome C”,PNAS, USA,95 (16), pp. 9567-9571, (Aug. 4, 1998).
Lochmüller, C.H., et al., “Chromatographic Resolution of Enantiomers—Selective Review”,Journal of Chromatography,113 (3), pp. 283-302, (Oct. 22, 1975).
Martel, R.R., et al., “Anti-inflammatory and Analgesic Properties of Etodolic Acid in Rats”,Canadian Journal of Physiology and Pharmacology,54 (3), pp. 245-248, (Jun. 1976).
Mooney, P.T., et al., “Cell Pathways' Exisulind ‘Aptosyn’ Demonstrates Potential to Delay Hormone Therapy in Post-Prostatectomy Men at Risk of Prostate Cancer Recurrence”, http://biz.yahoo.com/bw/000501/ga—cell—pa—1.html, 3 p., (May 2000).
Nardella, F.A., et al., “Enhanced Clearance of Leukemic Lymphocytes in B Cell Chronic Lymphocytic Leukemia (CLL) with Etodolac”,Arthritis&Rheumatism,42, (9) Supplement, Abstract No. 41, p. S56, (Sep. 1999).
Ricote, M., et al., “The Peroxisome Proliferator-Activated Receptor-γ is a Negative Regulator of Macrophage Activation”,Nature,391, pp. 79-82, (Jan. 1, 1998).
Riedel, D.A., et al., “The Epidemiology of Multiple Myeloma”,Hematology/Oncology Clinics of North America, Multiple Myeloma,6 (2), pp. 225-247, (Apr. 1992).
Royall, J.A., et al., “Evaluation of 2′,
Adachi Souchi
Carson Dennis A.
Cottam Howard B.
Leoni Lorenzo M.
Krass Frederick
Schwegman, Lundaberg, Woessner & Kluth P.A.
The Regents of The University of California
LandOfFree
Use of etodolac in the treatment of multiple myeloma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of etodolac in the treatment of multiple myeloma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of etodolac in the treatment of multiple myeloma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3533356